EGFR and colorectal carcinoma: Taken together, so-called quadruple-negative (no mutations in KRAS, NRAS, BRAF, PIK3CA) CRC is more likely to respond to EGFR inhibitors treatment and for those patients that do possess specific genetic mutations (BRAF and KRAS) clinical studies with new combination strategies are ongoing.